NO20001141L - Aromatisk C16-C20-substituert tetrahydro-prostaglandiner anvendbare som FP-agonister - Google Patents

Aromatisk C16-C20-substituert tetrahydro-prostaglandiner anvendbare som FP-agonister

Info

Publication number
NO20001141L
NO20001141L NO20001141A NO20001141A NO20001141L NO 20001141 L NO20001141 L NO 20001141L NO 20001141 A NO20001141 A NO 20001141A NO 20001141 A NO20001141 A NO 20001141A NO 20001141 L NO20001141 L NO 20001141L
Authority
NO
Norway
Prior art keywords
compounds
agonists
aromatic
useful
substituted tetrahydro
Prior art date
Application number
NO20001141A
Other languages
English (en)
Other versions
NO20001141D0 (no
Inventor
John August Wos
Mitchell Anthony Delong
Jr Jack S Amburgey
Biswanath De
Haiyan George Dai
Yili Wang
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO20001141D0 publication Critical patent/NO20001141D0/no
Publication of NO20001141L publication Critical patent/NO20001141L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Oppfinnelsen tilveiebringer nye PGF-analoger. Spesielt ved-rører foreliggende oppfinnelse forbindelser med en struktur i henhold til følgende formel:. hvori R( R, R, R, x, Y og Z er definert i beskrivelsen. . Denne-oppfinnelse omfatter også optiske isomerer, diaste-reomerer og enantiomerer med ovennevnte formel og farmasøy-tisk akseptable salter, biohydrolyserbare amider, estere og imider derav.Forbindelsene ifølge foreliggende oppfinnelse er nyttige for å behandle mange forskjellige sykdommer og tilstander, så som benlidelser og glaukom. Følgelig tilveiebringer oppfinnelsen ytterligere farmasøytiske sammensetninger omfat-tende disse forbindelser. Oppfinnelsen tilveiebringer enn ytterligere behandlingsmetoder for benlidelser og glaukom under anvendelse av disse forbindelser eller sammensetnin-gene inneholdende dem.
NO20001141A 1997-09-09 2000-03-06 Aromatisk C16-C20-substituert tetrahydro-prostaglandiner anvendbare som FP-agonister NO20001141L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5821797P 1997-09-09 1997-09-09
PCT/US1998/018339 WO1999012895A1 (en) 1997-09-09 1998-09-04 Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists

Publications (2)

Publication Number Publication Date
NO20001141D0 NO20001141D0 (no) 2000-03-06
NO20001141L true NO20001141L (no) 2000-05-04

Family

ID=22015427

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001141A NO20001141L (no) 1997-09-09 2000-03-06 Aromatisk C16-C20-substituert tetrahydro-prostaglandiner anvendbare som FP-agonister

Country Status (24)

Country Link
US (1) US5977173A (no)
EP (1) EP1012136B1 (no)
JP (1) JP2001515882A (no)
KR (1) KR20010023839A (no)
CN (1) CN1269786A (no)
AR (1) AR013477A1 (no)
AT (1) ATE270660T1 (no)
AU (1) AU731153B2 (no)
BR (1) BR9811774A (no)
CA (1) CA2303764C (no)
CO (1) CO4970731A1 (no)
DE (1) DE69824966T2 (no)
ES (1) ES2223141T3 (no)
HU (1) HUP0100638A3 (no)
ID (1) ID23971A (no)
IL (1) IL134839A0 (no)
NO (1) NO20001141L (no)
NZ (1) NZ503735A (no)
PE (1) PE115499A1 (no)
PL (1) PL339212A1 (no)
SK (1) SK3372000A3 (no)
TR (1) TR200000671T2 (no)
WO (1) WO1999012895A1 (no)
ZA (1) ZA988230B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513825A (en) 1999-03-05 2001-09-28 Procter & Gamble C 16 unsaturated FP-selective prostaglandins analogs
US6894175B1 (en) * 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
AU776375B2 (en) 1999-08-04 2004-09-09 Duke University Novel 2-decarboxy-2-phosphinico prostaglandin F analogs
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
KR100437873B1 (ko) * 2001-05-08 2004-06-26 연성정밀화학(주) 프로스타글란딘 유도체의 제조방법 및 그의 입체특이적출발물질
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US20060135609A1 (en) 2004-10-21 2006-06-22 Duke University Ophthamological drugs
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
RU2010121880A (ru) * 2007-10-31 2011-12-10 Памела ЛИПКИН (US) Композиции аналогов простагландина и способы лечения состояний, затрагивающих эпителий
US20100074857A1 (en) * 2008-09-23 2010-03-25 Pamela Lipkin Compositions and methods to treat epithelial-related conditions
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
EP2349242B1 (en) 2008-10-29 2018-12-05 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
WO2010077101A2 (ko) 2008-12-30 2010-07-08 조선대학교산학협력단 신규한 티아졸리딘디온 유도체 및 그의 용도
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US8394826B2 (en) 2009-05-01 2013-03-12 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
NZ628266A (en) 2009-11-09 2016-02-26 Allergan Inc Compositions and methods for stimulating hair growth
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
EP3811943B1 (en) 2013-03-15 2023-02-22 Aerie Pharmaceuticals, Inc. Compound for use in the treatment of ocular disorders
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
BR112019003945A2 (pt) 2016-08-31 2019-05-21 Aerie Pharmaceuticals, Inc. composições oftálmicas
CN110506037A (zh) 2017-03-31 2019-11-26 爱瑞制药公司 芳基环丙基-氨基-异喹啉酰胺化合物
WO2020056345A1 (en) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776938A (en) * 1958-05-28 1973-12-04 S Bergstrom Dihydro-pge1
US4011262A (en) * 1972-07-13 1977-03-08 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series
US4024179A (en) * 1972-11-08 1977-05-17 Pfizer Inc. Substituted ω-pentanorprostaglandins
IL50310A (en) * 1972-11-08 1977-08-31 Pfizer Dimethyl ketophosphonates
JPS5720305B2 (no) * 1973-02-28 1982-04-27
DE2365101A1 (de) * 1973-12-21 1975-07-10 Schering Ag Neue prostansaeurederivate und verfahren zu ihrer herstellung
DE2460990A1 (de) * 1974-12-21 1976-07-01 Hoechst Ag Neue prostaglandin-analoga und verfahren zu ihrer herstellung
GB1507211A (en) * 1975-02-14 1978-04-12 Ono Pharmaceutical Co Prostaglandin analogues
GB1506817A (en) * 1975-03-31 1978-04-12 Upjohn Co Prostaglandins
DE2517771A1 (de) * 1975-04-18 1976-10-28 Schering Ag Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung
US4051238A (en) * 1976-06-03 1977-09-27 The Upjohn Company Treatment of genital tract diseases of domestic animals with prostaglandins
DE2737808A1 (de) * 1976-08-27 1978-03-16 Pfizer 2-substituierte aryl-heterocyclische omega-pentanorprostaglandine
US4206151A (en) * 1978-12-21 1980-06-03 American Cyanamid Company 15-Deoxy-16-hydroxy-16-vinyl or cyclopropyl prostan-1-ols of the E, A and F series
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
JP2721414B2 (ja) * 1988-09-06 1998-03-04 フアーマシア・アンド・アツプジヨン・アー・ベー 縁内障または眼圧亢進の治療のためのプロスタグランジン誘導体
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
TW249226B (no) * 1990-04-04 1995-06-11 Aderk Ueno Kk
US5302617A (en) * 1990-04-27 1994-04-12 Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
DE4024347A1 (de) * 1990-07-27 1992-01-30 Schering Ag Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5332730A (en) * 1992-10-16 1994-07-26 Allergan, Inc. Azido derivatives of cyclopentane heptanoic or heptenoic acid
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5545665A (en) * 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US6169111B1 (en) * 1995-06-07 2001-01-02 Alcon Laboratories, Inc. Conformationally rigid aryl prostaglandins for use in glaucoma therapy
WO1997023225A1 (en) * 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
DE69714698T2 (de) * 1996-06-10 2002-12-05 Sucampo Ag, Zug Endothelin-antagonisten
DE69714274T3 (de) * 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. Fluorierte prostaglandinderivate und medikamente
AU5436198A (en) * 1996-11-12 1998-06-03 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
US6353014B1 (en) * 1996-11-12 2002-03-05 Alcon Laboratories, Inc. 15-ketal postaglandins for the treatment of glaucoma or ocular hypertension
CA2293325C (en) * 1997-05-09 2008-09-02 The Mount Sinai School Of Medicine Of The City University Of New York 8-iso-prostaglandins for glaucoma therapy

Also Published As

Publication number Publication date
TR200000671T2 (tr) 2000-07-21
HUP0100638A3 (en) 2002-12-28
EP1012136B1 (en) 2004-07-07
NO20001141D0 (no) 2000-03-06
JP2001515882A (ja) 2001-09-25
PL339212A1 (en) 2000-12-04
IL134839A0 (en) 2001-05-20
CA2303764A1 (en) 1999-03-18
ES2223141T3 (es) 2005-02-16
EP1012136A1 (en) 2000-06-28
ID23971A (id) 2000-06-14
NZ503735A (en) 2001-05-25
SK3372000A3 (en) 2000-10-09
CN1269786A (zh) 2000-10-11
DE69824966D1 (de) 2004-08-12
HUP0100638A2 (hu) 2001-07-30
US5977173A (en) 1999-11-02
AU731153B2 (en) 2001-03-22
ZA988230B (en) 1999-03-09
DE69824966T2 (de) 2005-04-07
WO1999012895A1 (en) 1999-03-18
AU9219398A (en) 1999-03-29
KR20010023839A (ko) 2001-03-26
BR9811774A (pt) 2000-08-29
ATE270660T1 (de) 2004-07-15
CA2303764C (en) 2005-02-15
CO4970731A1 (es) 2000-11-07
AR013477A1 (es) 2000-12-27
PE115499A1 (es) 2000-02-03

Similar Documents

Publication Publication Date Title
NO20001141L (no) Aromatisk C16-C20-substituert tetrahydro-prostaglandiner anvendbare som FP-agonister
CA2303801A1 (en) Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
TR200000670T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
NO20024521L (no) Heterocyklisk sidekjede-inneholdende metalloproteaseinhibitorer
HU195479B (en) Process for producing (/alkyl-sulfonamido/-phenyl)-alkyl-amines
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
NO20050134L (no) Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse
NO20014241L (no) C16-umettede FP-selektive prostaglandinanaloger
EP0354777A3 (en) 3-(4-piperidine)-5-(2-sulfonylaminoethyl) indole derivatives
HK1076107A1 (en) Pyrrolidine derivatives as oxytocin antagonists
CA2380326A1 (en) Novel 2-decarboxy-2-phosphinico prostaglandin f analogs
NO20001169L (no) 6,9-bro erythromycinderivater
NO20002099L (no) 6,11-bro-erytromycinderivater
CA2364944A1 (en) C16 unsaturated fp-selective prostaglandins analogs
AU2003249575A8 (en) A process for preparing pharmaceutical compositions containing 4-aminoquinolines compounds for treatment of inflammatory disorders of the eye and compositions resulting therefrom
IL148875A0 (en) Sulfonyl hydrazide derivatives, their preparation and pharmaceutical compositions containing them
US5010097A (en) Novel compounds
JPH03106893A (ja) 骨吸収阻害剤としてのビスホスホン酸類のアシルオキシメチルエステル
JP2001505556A (ja) 眼圧降下剤としての１５―フルオロプロスタグランジン
CA2324343A1 (en) C11 oxymyl and hydroxylamino prostaglandins useful as medicaments
NO20045132L (no) Benzo(c)kinolizinderivater, deres fremstilling og anvendelse som 5alfa- reduktaseinhibitorer
NO20024481L (no) Difluor smörsyre metalloproteaseinhibitorer
BR9909268A (pt) C11 oximil e hidroxilamino prostaglandinas úteis como agonistas de fp
US4876282A (en) 1-Phenylalkylamines as selective serotonin uptake inhibitors
NO995030L (no) 5-(2-imidazolinylamino)benzimidazolforbindelser nyttige som <alfa>-2-adrenoseptoragonister